Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...

bioTheranostics, Inc's Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be ...

Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Rate of medical ...

Please provide your email address to receive an email when new articles are posted on . The Endocrine Self-Assessment Program In-Training Examination is a strong predictor of pass/fail outcomes on the ...

First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration Findings from 11 ...

New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) identifies postmenopausal women with ...

Norman Parathyroid Center, Clayman Thyroid Center, and Carling Adrenal Center Expand Their Lead as the World’s ...